Combination of androgen receptor inhibitor enzalutamide with the CDK4/6 inhibitor ribociclib in triple negative breast cancer cells

Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer (BC) that currently lacks specific therapy options. Thus, chemotherapy continues to be the primary treatment, and developing novel targets is a top clinical focus. The androgen receptor (AR) has emerged as a therapeutic t...

Descripción completa

Detalles Bibliográficos
Autores principales: Choupani, Edris, Madjd, Zahra, Saraygord-Afshari, Neda, Kiani, Jafar, Hosseini, Arshad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9779032/
https://www.ncbi.nlm.nih.gov/pubmed/36548336
http://dx.doi.org/10.1371/journal.pone.0279522

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9779032/
https://www.ncbi.nlm.nih.gov/pubmed/36548336
http://dx.doi.org/10.1371/journal.pone.0279522

Ejemplares similares